LEN vs XBIO · rev $34.19B vs rev $2.5M
LEN (LEN) versus Xenetic Biosciences Inc (XBIO) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Xenetic Biosciences Inc (XBIO) is a biotechnology company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported XBIO revenue for 2024-12-31 was $2.5M. Net income was -$4.0M. Revenue was down 1.6% from 2023-12-31 to 2024-12-31. XBIO currently screens at market cap $5.7M.
LEN currently screens at market cap $0. XBIO currently screens at market cap $5.7M.
Not investment advice. Open the LEN and XBIO stock pages for the full models.
Not investment advice.